Identify Key Prescribing Factors That Influence Prescription Patterns for Systemic Therapy in Renal Cancer
Posted on: Friday, 16 November 2007, 06:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c74522) has announced the addition of "Stakeholder Insight: Renal Cancer - Targeted therapies rapidly take hold of market" to their offering.
Introduction
In the 7 major markets, we estimate that the incidence of RCC in 2007 will total 86,800 cases. Around 25% of all RCC patients are diagnosed with Stage IV disease; the 2-year survival rate for these patients is around 23%. This low survival rate and the fact that a significant proportion of Stage IIII patients relapse with Stage IV disease mean there is significant unmet need in RCC.
Scope
Analysis of RCC market based on a survey of 180 renal cancer specialists, supported by interviews carried out with key opinion leaders Segmentation of renal cancer patient population by disease subtype, disease stage at presentation and proportion receiving surgery and/or drug therapy In-depth analysis of treatment patterns in RCC by line of therapy, including most commonly prescribed drug regimens in 7 major markets Ranking of key prescribing influences in RCC, brand assessment of existing drug therapies, unmet needs and late-phase pipeline overview
Highlights
Pfizers Sutent (sunitinib) is established as the standard-of-care for the first-line treatment of Stage IV RCC in most of the 7 major pharmaceutical markets. Bayer/Onyxs Nexavar (sorafenib) is the most commonly prescribed therapy in the second-line for Sutent-refractory patients. Wyeths Torisel (temsirolimus) will soon be used in some poor-prognosis patients in the first-line and Genentech/Roches Avastin (bevacizumab) may capture some of Sutents first-line market share. Both drugs are also likely to compete for a share of the second-line market in Sutent-refractory patients. Due to high levels of unmet need in renal cancer, there is considerable activity in the late-phase renal cancer pipeline, with 9 drugs in Phase III development including 4 immunotherapies and 5 targeted therapies. The most promising drugs are Novartiss Certican (everolimus) and GlaxoSmithKlines pazopanib.
Reasons to Purchase
Identify key prescribing factors that influence prescription patterns for systemic therapy in renal cancer Examine the significant unmet need within renal cancer and identify opportunities for new product development Enhance commercial positioning by increasing understanding of current dynamics within the renal cancer market
For more information, visit http://www.researchandmarkets.com/reports/c74522
Source: Datamonitor
Source: Business Wire
Related Articles
- U.S. Compression Therapy Market to Reach $1.16 Billion in 2015, Finds Frost & Sullivan
- Key Challenges and Issues Facing the Cancer Cell Therapy Markets
- New Report Describes the Segment of the Cell Therapy Market Aimed Specifically at Cancer Therapy
- Antisoma Starts Phase I Clinical Trial of AS1409 in Renal Cancer and Melanoma
- Unmet Needs Remain in Renal Cancer Despite New Treatments
- Osiris Therapeutics Reports Positive Results for Prochymal(TM) As a Rescue Agent in Pediatric Patients With End-Stage Graft Vs. Host Disease
- Renal Cancer Drug Pipeline Update Lists All Drugs and Gives You a Progress Analysis on Each One of Them
- Growing Incidence of Acute Renal Failure Fuels Growth in the European Renal Therapy Market
- Research And Markets: Will High Investment In The Cancer Therapy Market Lead To Improvements?
 |
 |
User Comments (0)
RSS Feeds